Supplemental Figure 1



Supplemental Figure 1. Responsiveness of different molecular subtypes breast cancer cell lines to TGFβ as measured by PAI-1 expression levels. Indicated cell lines of basal **(A)** and luminal **(B)** breast cancer intrinsic subtypes were transduced with non-target (NT) or MYC shRNA (MYC KD), and treated with TGFβ as indicated. PAI-1 transcript levels are presented as relative quantification, normalized to GAPDH. Error bars, SEM; * $p<0.5$; ** $p<0.01$.

Supplemental Figure 2



Supplemental Figure 2. TGFβ and MYC knockdown inhibit cell proliferation. (A) TGFβ and MYC KD inhibit EdU incorporation, but knockdown of integrin αv (ITGAV) does not. Representative pictures showing proliferating cells (in green). Scale bars, 50 μm. **(B)** Quantification of EdU positive cells compared to total number of cells. Error bars, SEM; * $p<0.5$; ** $p<0.01$; *** $p<0.001$.

Supplemental Figure 3



Supplemental Figure 3. MYC reduction potentiates TGFβ induced invasive phenotype in SUM149 cells. TGFβ treatment and MYC knockdown stimulate invasion of SUM149 cells through a potentiation effect. Data plotted as error±SEM, *, $p<0.05$; **, $p<0.01$; ***, $p<0.005$.

Supplemental Figure 4



Supplemental Figure 4. Pharmacological inhibition of SRC blocks the potentiation effect of simultaneous MYC knockdown and TGFβ treatment on increased levels of integrin αvβ3. MCF10A cells were treated with pharmacological inhibitors of SRC, Dasatinib **(A)** and PP2 **(B)**, for 72h. Levels of indicated proteins were assessed by western blot.

Supplemental Figure 5



Supplemental Figure 5. Pharmacological inhibition of MYC mimics the effect of MYC knockdown on integrin αvβ3 levels, in a dose dependent manner. (A) MCF10A cells were lentivirally transduced with either non-target or MYC targeting shRNAs and treated with MYC inhibitors, JQ1 (250 nM) or MI2 (30 μM), for 72h or with TGFβ (25 ng/ml) for 18h. Protein levels were assessed by western blot. **(B-C)** In MCF10A cells, increasing concentrations of MI2 **(B)** and JQ1 **(C)** progressively increase levels of integrin αvβ3**. (D)** Treatment of MCF12A cells with increasing concentrations of JQ1 or MI2, progressively increases levels of integrin αvβ3**.**